Patent ID: 7166438
Filing Date: 2007-01-23
Classification: A61P,G01N

Abstract:
1. A method of screening a group of test substances for one or more ligands to be administered as effective ingredients in a method of treating neuro-degeneration, said test substances being selected from the group consisting of estrogens and compounds having estrogen activity, said method of screening comprising the steps of: a) providing a cell-free or enzymatic assay system for each of said test substances, said cell-free or enzymatic assay system comprising an estrogen receptor for said test substances and a co-present steroid receptor coactivator-1, and fragments thereof; b) experimentally determining half-maximally effective ligand concentrations (EC c) selecting said one or more of said test substances if said half-maximally effective ligand concentration (EC d) providing a cellular or tissue assay system comprising an estrogen receptor and an estrogen receptor-driven reporter gene; e) experimentally determining half-maximally effective ligand concentrations (EC f) selecting those of said one or more test substances having said half-maximally-effective ligand concentrations that transcriptionally activate said cellular or tissue assay system and that are less than or equal to 10 nmol/l as said one or more ligands for said method of treating said neuro-degeneration.